|
Home | Medical-Newswire.Com:
|
(Medical-NewsWire.com, November 04, 2015 ) GlobalData estimates the 2014 sales for growth hormone deficiency (GHD) at approximately $1.26 billion across the 7MM covered in this report. The market will grow moderately at a CAGR of 4.08% during the 10-year forecast period, generating sales of approximately $1.88 billion at the end of 2024. The US market is expected to grow the fastest of the three regions, recording a CAGR of 4.88% and generating around 59% of global sales in 2024. The major driver for this growth across the 7MM will be the launch of long-acting biobetter growth hormones (GH), which will rapidly take away shares from the currently marketed daily injectable growth hormones.
To Get Sample Copy of Report visit @ http://www.researchmoz.us/enquiry.php?type=S&repid=443290
Highlights
Key Questions Answered
- Overall, the greatest unmet need in the GHD space is the issue with treatment adherence and compliance. There are other prominent unmet needs highlighted by the Key Opinion Leaders (KOLs). What are these? Will the pipeline drugs fulfil these unmet needs of the market?
- The 10-year forecast period will mark the launch of six pipeline long-acting GH drugs. How will the sales of the existing drugs be impacted? Which of the pipeline drugs will have the highest peak sales at the highest CAGR, and why?
- What are the roles of payers in this highly competitive disease space? How does this affect market shares of the GH brands, especially in the US? What are the chances of reimbursement for the long-acting GH drugs in pipeline?
Key Findings
- The major driver for growth in the GHD market during the forecast period will be the launch of six long-acting GH biobetters with less frequent dosing regimens. These will not only boost the use of GH, but will in addition increase adherence and compliance in patients.
- KOLs interviewed by GlobalData opined that these long-acting biobetters will eventually replace most of the patient shares of currently marketed GH drugs during the forecast period.
- In other interviews, US payers revealed to GlobalData the current trend of GH manufacturers negotiating with insurance companies as a means of gaining market access for their particular brand.
- Low disease awareness and stringent regulatory policies lead to sub-optimal dosing and treatment outcomes in the Japanese market.
- Companies in the early-stage GHD space demonstrate two major trends development of long-acting GH formulations and innovation in GH delivery strategies.
Scope
- Overview of GHD, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
- Annualized GHD therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2014 and forecast for ten years to 2024.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the GHD therapeutics market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs.
- Analysis of the current and future market competition in the global GHD therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. Additionally a list of acquisition targets included in the pipeline product company list.
- Develop business strategies by understanding the trends shaping and driving the GHD therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the GHD therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track drug sales in the 7MM GHD therapeutics market from 2014-2024.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Browse Detail Report With TOC @ http://www.researchmoz.us/opportunityanalyzer-growth-hormone-deficiency-opportunity-analysis-and-forecast-to-2024-report.html
Table of Contents
1.1 List of Tables 15
1.2 List of Figures 17
2 Introduction 18
2.1 Catalyst 18
2.2 Related Reports 18
3 Disease Overview 19
3.1 Etiology and Pathophysiology 19
3.1.1 Etiology 19
3.1.2 Pathophysiology 20
3.2 Symptoms 22
3.3 Diagnosis 22
3.4 Prognosis 23
3.5 Quality of Life 23
4 Epidemiology 25
4.1 Disease Background 25
4.1.1 GHD in Children 25
4.1.2 GHD in Adults 26
4.2 Risk Factors and Comorbidities 26
4.3 Global Trends 28
4.3.1 GHD in Children 29
4.3.2 GHD in Adults 31
4.4 Forecast Methodology 32
4.4.1 Sources Used 36
4.4.1.1 7MM 36
4.4.1.2 Diagnosed Cases of GHD in Children 37
4.4.1.3 Diagnosed Cases of GHD in Adults 38
4.4.1.4 GHD Etiological Classification in Children 38
4.4.1.5 GHD Etiological Classification in Adults 39
4.4.2 Sources Not Used 40
4.4.3 Forecast Assumptions and Methods 41
4.4.3.1 Temporal Trends 41
4.4.3.2 Sex-Specific Trends 41
4.4.3.3 Diagnosed Prevalent Cases of GHD in Children 41
4.4.3.4 Diagnosed Prevalent Cases of GHD in Adults 42
4.4.3.5 GHD Etiological Classification in Children 43
4.4.3.6 GHD Etiological Classification in Adults 43
4.5 Epidemiological Forecast of GHD (2014-2024) 44
4.5.1 Diagnosed Prevalent Cases of GHD 44
4.5.2 Diagnosed Prevalent Cases of GHD by Sex 46
4.5.3 Diagnosed Prevalent Cases of GHD by Age 47
4.5.3.1 Diagnosed Prevalent Cases of GHD in Children 47
4.5.3.2 Diagnosed Prevalent Cases of GHD in Adults 49
4.5.4 Age-Adjusted Diagnosed Prevalence of GHD 50
4.5.5 Diagnosed Prevalent Cases of GHD in Children by Etiological Classification 51
4.5.6 Diagnosed Prevalent Cases of GHD in Adults by Etiological Classification 52
4.6 Discussion 53
4.6.1 Epidemiological Forecast Insight 53
4.6.2 Limitations of the Analysis 54
4.6.3 Strengths of the Analysis 55
Make an Enquiry of this report @ http://www.researchmoz.us/enquiry.php?type=E&repid=443290
About ResearchMoz
ResearchMoz is the one stop online destination to find and buy market research reports & Industry Analysis. We fulfill all your research needs spanning across industry verticals with our huge collection of market research reports. We provide our services to all sizes of organizations and across all industry verticals and markets. Our Research Coordinators have in-depth knowledge of reports as well as publishers and will assist you in making an informed decision by giving you unbiased and deep insights on which reports will satisfy your needs at the best price.
For More Information Kindly Contact:
ResearchMoz
Mr. Nachiket Ghumare,
Tel: +1-518-621-2074
USA-Canada Toll Free: 866-997-4948
Email: sales@researchmoz.us
Website: http://www.researchmoz.us/
Researchmoz Global Pvt.Ltd
Researchmoz
+1-518-621-2074
sales@researchmoz.us
Source: EmailWire.Com 
Source: EmailWire.com
|
|
|
|
